Balyasny Asset Management
APLS

Balyasny Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Balyasny Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120,000
Closed -$3.01M – 2863
2025
Q4 		$3.01M Buy
+120,000
New +$2.82M ﹤0.01% 1664

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management's APLS Position: Q1 2026 in Review

Balyasny Asset Management increased its Apellis Pharmaceuticals (APLS) stake by 2,844% in Q1 2026, buying an estimated $39.9M and bringing the position to 1,917,501 shares worth $77.1M. The position accounts for 0.1% of the portfolio, ranked #226.

Balyasny Asset Management first reported a position in APLS in Q2 2018 and has held it in 14 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Balyasny Asset Management held 1,917,501 shares of Apellis Pharmaceuticals worth $77.1M as of Q1 2026.
  • Balyasny Asset Management bought 1,852,368 Apellis Pharmaceuticals shares in Q1 2026, an estimated $39.9M.
  • Apellis Pharmaceuticals made up 0.1% of Balyasny Asset Management's portfolio in Q1 2026, its #226 holding.
  • Balyasny Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 14 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.